Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived
series of β2-adrenoceptor agonists have been prepared and evaluated for their potential as …

Here, we describe the preclinical pharmacological profile of 5-[(R)-2-(5, 6-diethyl-indan-2-
ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (indacaterol), a novel, chirally pure …

Indacaterol is a novel once daily inhaled β2 adrenoceptor agonist in clinical development.
This study compared the properties of indacaterol with salmeterol, formoterol, and albuterol …

Abediterol is a novel long-acting β 2-adrenoceptor agonist (LABA) currently in development
for once-daily combination maintenance therapy of asthma and COPD. This study …

The present study examined the bronchodilator and safety profiles of single-dose
indacaterol in intermittent or persistent asthma. In the present double-blind crossover study …

Abediterol is a novel potent, long-acting inhaled β2-adrenoceptor agonist in development for
the treatment of asthma and chronic obstructive pulmonary disease. Abediterol shows …

The design and profile of a series of indole containing long acting β2-adrenoceptor agonists
is described. Evaluation of these analogues using an in vitro guinea pig trachea tissue …

Indacaterol is a novel β2-adrenoceptor agonist in development for the once-daily treatment
of asthma and chronic obstructive pulmonary disease. The present study evaluated the …

The synthesis of a series of indacaterol analogues in which each of the three structural
regions of indacaterol are modified in a systematic manner is described. Evaluation of the …

Background. Indacaterol is a new once-daily inhaled β2-agonist in clinical development for
asthma as a component of a fixed-dose combination with an inhaled corticosteroid …